A set of twelve patient-derived IDHmt cell cultures was established....we selected one compound from each subclass for further validation: gemcitabine, teniposide, daunorubicin, romidepsin, dactinomycin, regorafenib, and omacetaxine. We replaced the proteasome inhibitor bortezomib with marizomib....For the taxanes we opted to include paclitaxel...This validation set revealed high overall sensitivity to each of the compounds...Our drug screening studies reveal lack of sensitivity to IDHmt inhibitors, but sensitivity to a set of nine available anti-cancer agents.